Polymorphism of the HLA system and weak antibody response to BNT162b2 mRNA vaccine

HLA. 2022 Mar;99(3):183-191. doi: 10.1111/tan.14546. Epub 2022 Jan 23.

Abstract

The polymorphism of the HLA system has been extensively studied in COVID-19 infection, however there are no data about the role of HLA on vaccine response. We report here the HLA-A, -B, -C, and DRB1 allelic frequencies of n = 111 individuals after BNT162b2 mRNA vaccine, selected on the basis of lower antibody levels (<5% percentile) after the second dose among a total of n = 2569 vaccinees, and compare them with the frequencies of a reference population. We found that differences in the frequencies of the alleles HLA-A*03:01, A*33:03, B*58:01 and at least one haplotype (HLA-A*24:02~C*07:01~B*18:01~DRB1*11:04) are associated with a weaker antibody response after vaccination, together with the age of vaccinees. Our results might suggest a role played by some HLA alleles or haplotypes in antibody production after the BNT162b2 mRNA vaccine, giving insights into the tracking of potentially susceptible individuals across populations. Further studies are needed to better define our exploratory findings and dissect the role of HLA polymorphism on response to anti-COVID-19 vaccines.

Keywords: COVID-19; HLA; antibody; mRNA vaccine; spike protein.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alleles
  • Antibodies, Viral / immunology
  • Antibody Formation*
  • BNT162 Vaccine / immunology*
  • COVID-19* / prevention & control
  • Gene Frequency
  • HLA-DRB1 Chains* / genetics
  • Haplotypes
  • Humans
  • SARS-CoV-2
  • Vaccines, Synthetic / immunology
  • mRNA Vaccines

Substances

  • Antibodies, Viral
  • HLA-DRB1 Chains
  • Vaccines, Synthetic
  • BNT162 Vaccine